Personalis Investor Relations Material

Personalis Cancer Genome Tests allow physicians to classify patients' tumors based on shared genomic changes and match them with therapies known to be effective for those alterations, such as targeted therapies, immunotherapies, or clinical trials. Its software solutions include ACE Clinical that provides clinical researchers with data-driven insights into biomarkers and biologic drug mechanisms; ACE Biology that interprets human genome information to allow researchers to gain insight into potential oncology drug targets and underlying mechanisms of drug resistance; and Product Management platform that allows customers to order personalized tests. The company was formerly known as Illumina TRUseq Custom Amplicon and changed its name to Personalis, Inc. in May 2013. Personalis, Inc. was founded in 2012 and is headquartered in Menlo Park, California.